Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Beta-Blocker, Antiarrhythmic Agent class II
Original Date: 
June 1996
Revised Date: 
February 2021
  • Tachyarrhythmias and hypertension
  • Palliation of Tetralogy of Fallot
  • Neonatal thyrotoxicosis
  • IV direct: over 10 minutes
  • PO
  • IV: 0.01 - 0.15 mg/kg/dose Q 6-8 H.  Titrate dose slowly
  • PO: 1 - 5 mg/kg/day divided Q 6-8 H
    • Thyrotoxicosis: 2 mg/kg/day divided Q 6-12 H
      • Available as a suspension and 10 mg tablet.  If unable to take suspension round dose to the nearest 1/4 tablet
Side Effects: 
  • CVS: bradycardia, hypotension, heartblock
  • Endrocrine and metabolic: hypoglycemia, hyperglycemia
  • Hematologic: agranulocytosis
  • Respiratory: bronchospasm
Parameters to Monitor: 
  • ECG- acutely
  • BP, HR
  • Serum electrolytes
  • Serum glucose: consider blood glucose monitoring q6h for the first 24 - 48 hours following initiation /dose titration.  Blood glucose ac feeds and/or 1-2 hours post-dose .

- Solutions Compatible: D5W, 0.9 % NaCl, dextrose-saline combinations

- Y-site Compatible: dobutamine, heparin, KCl, milrinone, morphine


- Taketomo CK,  Hodding JH, Kraus DM.  Pediatric & Neonatal Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc.; 2015

- Trissel LA. Handbook on Injectable Drugs. 19th Editions. Bethesda: American Society of Health-System Pharmacists; 2017

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.